Halozyme Therapeutics' net profit under GAAP for 9 months of 2020 was $55.921 million, against a loss of $37.843 million in the previous year. Revenue increased 2.5% to $145.891 million, against $142.327 million in the previous year.
Halozyme Therapeutics' net profit under GAAP for 9 months of 2020 was $55.921 million, against a loss of $37.843 million in the previous year. Revenue increased 2.5% to $145.891 million, against $142.327 million in the previous year. 
halozyme.com
English (US) 